Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any hyperinsulinemic hypoglycemia in which the cause of the disease is a mutation in the KCNJ11 gene.
Features include always present findings: Hyperinsulinemic hypoglycemia and Nesidioblastosis. 5 total HPO annotations.
Organ System
Phenotype Count |
|---|
Example Features |
|---|
Digestive system | 1 | Pancreatic islet-cell hyperplasia |
KCNJ11 encodes potassium inwardly rectifying channel subfamily J member 11 (390 aa). Inward rectifier potassium channel that forms the pore of ATP-sensitive potassium channels (KATP), regulating potassium permeability as a function of cytoplasmic ATP and ADP concentrations in many different cells. Highest expression in Muscle Skeletal (87.1 TPM) and Brain Cerebellum (37.4 TPM).
Hyperinsulinemic hypoglycemia, familial, 2 is caused by mutations in the KCNJ11 gene on chromosome 11.
The KCNJ11 protein participates in KCNJ11 tetramer:ABCC8 mutants, KCNJ11 tetramer:ABCC8:Mg2+:ADP tetramer, and KCNJ11:ATP tetramer:ABCC8 tetramer pathways.
KCNJ11 is classified as a druggable target (Druggable Genome and Ion Channel categories) with score 1.2.
Genetic testing for KCNJ11 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for hyperinsulinemic hypoglycemia, familial, 2 has been reported in the published literature.
Phenotype severity distribution: 2 always present features.
1 clinical trial registered. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
88 publications have been identified in PubMed for hyperinsulinemic hypoglycemia, familial, 2. Research spans Case Report / Case Series (35%), Review / Meta-Analysis (22%), and Basic Science / Preclinical (17%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 31 | 35% |
Research summaries | 19 | 22% |
Laboratory research | 15 | 17% |
Disease patterns and progression | 10 | 11% |
Other research | 5 | 6% |
Testing and diagnosis research | 4 | 5% |
Clinical study results | 4 | 5% |
Wong T (2026). [PMID: 41982675](https://pubmed.ncbi.nlm.nih.gov/41982675/). *Front Pharmacol*. [Review / Meta-Analysis]
Zhang QT (2026). [PMID: 41582760](https://pubmed.ncbi.nlm.nih.gov/41582760/). *Zhongguo Dang Dai Er Ke Za Zhi*. [Review / Meta-Analysis]
González-Llorens N (2026). [PMID: 41201695](https://pubmed.ncbi.nlm.nih.gov/41201695/). *Paediatr Drugs*. [Review / Meta-Analysis]
Widmer A (2026). [PMID: 40705962](https://pubmed.ncbi.nlm.nih.gov/40705962/). *J Clin Endocrinol Metab*. [Case Report / Case Series]
Rosenfeld E (2026). [PMID: 41980002](https://pubmed.ncbi.nlm.nih.gov/41980002/). *Horm Res Paediatr*. [Review / Meta-Analysis]
Scala R (2026). [PMID: 40272924](https://pubmed.ncbi.nlm.nih.gov/40272924/). *Diabetes*. [Case Report / Case Series]
States LJ (2026). [PMID: 41539914](https://pubmed.ncbi.nlm.nih.gov/41539914/). *PET Clin*. [Review / Meta-Analysis]
Sanders VR (2026). [PMID: 41795819](https://pubmed.ncbi.nlm.nih.gov/41795819/). *Horm Res Paediatr*. [Case Report / Case Series]
Rossi A (2026). [PMID: 42105432](https://pubmed.ncbi.nlm.nih.gov/42105432/). *Mol Genet Metab*. [Review / Meta-Analysis]
Kantzavelou A (2026). [PMID: 41978437](https://pubmed.ncbi.nlm.nih.gov/41978437/). *J Clin Res Pediatr Endocrinol*. [Case Report / Case Series]
Data assembled from 7 of 12 sources · Last updated Sep 19, 2026, 6:55 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center